SL Science Submits Orphan Drug Designation Request to FDA for GDT Cell Therapy in Glioblastoma
() -- SL Science (SLBT) said Friday it has submitted an orphan drug designation request to the US Food and Drug Administration for its Gamma Delta T therapy, named Vdelta2+ Gamma Delta T Cells, for the treatment of glioblastoma multiforme. The biomedical company further said that the FDA's Office of Orphan Products Dev